Abstract-This study was designed to determine the influence of increased superoxide anion in neuronal nitric oxide synthase (nNOS)-dependent regulation of afferent arterioles in spontaneously hypertensive rats (SHR). Afferent arteriolar diameters of male Wistar-Kyoto rats (WKY) and SHR were assessed in vitro with the blood-perfused juxtamedullary nephron technique and averaged 21.6Ϯ1.6 (nϭ6) and 18.8Ϯ1.2 (nϭ7) m, respectively. The superoxide dismutase mimetic Tempol (1, 10, and 100 mol/L) did not influence afferent arterioles of WKY but significantly increased afferent arteriolar diameters of SHR by 20.6Ϯ5.5%, 25.2Ϯ5.4%, and 23.3Ϯ4.9%, respectively. In WKY (nϭ6), the nNOS inhibitor S-methyl-L-thiocitrulline (L-SMTC; 10 mol/L) and the NOS inhibitor N -nitro-L-arginine (L-NNA; 100 mol/L) significantly decreased afferent arteriolar diameters (19.6Ϯ1.6 m) by 11.9Ϯ3.1% and 21.0Ϯ3.9%, respectively. In SHR (nϭ7), L-SMTC did not influence afferent arteriolar diameters (21.0Ϯ1.5 m), but L-NNA exerted an afferent arteriolar constriction (14.8Ϯ3.2%) that was similar to the response observed in WKY. Experiments were also performed in the presence of 100 mol/L Tempol. In afferent arterioles of WKY (nϭ6), Tempol treatment did not modulate the basal diameters (21.5Ϯ1.2 m) or the constrictor response to L-SMTC (10.6Ϯ2.1%) or L-NNA (19.3Ϯ3.3%). In SHR (nϭ8), Tempol significantly increased afferent arteriolar diameters by 22.5Ϯ4.3% and enhanced afferent arteriolar constrictor responses to L-SMTC (18.4Ϯ2.7%) and L-NNA (31.9Ϯ2.6%). However, the nitric oxide donor S-nitroso-N-acetylpenicillamine (10 mol/L), which similarly increased afferent arteriolar diameters (17.2Ϯ2.3%, nϭ6), did not affect afferent arteriolar responses to L-SMTC (1.5Ϯ2.7%) or L-NNA (18.6Ϯ2.3%). These suggest that superoxide anion inhibits the control of afferent arteriolar diameters by nNOS in SHR. Key Words: Tempol Ⅲ nitric oxide synthase Ⅲ arterioles Ⅲ rats, spontaneously hypertensive Ⅲ kidney N itric oxide (NO) is recognized as a major paracrine regulator of renal microvascular tone. 1 Inhibition of NO synthase (NOS) causes renal microvascular constriction with consequent decreases in renal blood flow and glomerular filtration rate. Therefore, renal NO deficiency may theoretically lead to the development of hypertension. However, constitutive NOS activity has been reported to be maintained in the kidneys of various models of hypertension. [2] [3] [4] [5] In kidneys of spontaneously hypertensive rats (SHR), constitutive NOS activity is also maintained or elevated, 6 -9 suggesting that renal NO production is not reduced. However, the endothelium-dependent relaxation of renal vasculatures has been reported to be impaired in this model of hypertension. 10, 11 This finding can be explained by the reduced production of NO-independent vasodilators, such as endothelium-derived hyperpolarizing factor, or a decrease in NO bioavailability. Recent studies have demonstrated that superoxide anion (O 2 Ϫ ) production is increased in the aorta of stroke-prone SHR 12,13 and in the renal cortex of SHR. 14 Because O 2 Ϫ scavenges NO to form peroxynitrite (ONOO Ϫ ), a shorter-lived and less potent vasorelaxant than NO, 15 the increase in O 2 Ϫ production may cause the decrease in NO bioavailability that has been observed in the aorta of stroke-prone SHR, 12,13 the mesenteric arteries of SHR, 16 and the afferent arterioles of streptozotocintreated diabetic rats. 17 The present study was performed to evaluate the influence of constitutive NOS activity, that is, neuronal NOS (nNOS) and endothelial NOS (eNOS), on the afferent arteriolar diameters in SHR and the normotensive control rats, WistarKyoto rats (WKY). We hypothesized that the influence of NOS on afferent arterioles in SHR would be altered by the decrease in NO bioavailability resulting from an increase in O 2 Ϫ activity. To test this hypothesis, we used the in vitro blood-perfused juxtamedullary nephron technique combined with videomicroscopy. 4,18 -22 Received October 
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Methods

Assessment of Afferent Arteriolar Diameter
The experiments were performed in accordance with the guidelines and practices established by the Keio University Animal Care and Use Committee. Afferent arteriolar diameter was assessed in vitro with the blood-perfused juxtamedullary nephron technique combined with videomicroscopy, as previously described. 4,18 -22 Briefly, each experiment used 2 male WKY or SHR (Charles River Labs), weighing 300 to 350 g, with 1 rat serving as the blood donor and the second rat serving as the kidney donor. The rats were allowed free access to water and standard rat chow (Clea Japan) before the experiments. The rats were anesthetized with sodium pentobarbital (50 mg/kg IP). Donor blood was collected into a heparinized (500 U) syringe and centrifuged to separate the plasma and cellular fractions. Plasma oncotic pressure was adjusted to 18 mm Hg by the addition of BSA (Sigma Chemical Co). After processing of the plasma through filters, erythrocytes were added to achieve a hematocrit of 33%. This reconstituted blood was stirred continuously in a closed reservoir pressurized with a 95% O 2 , 5% CO 2 gas mixture.
The right renal artery of the kidney donor was cannulated and perfused with Tyrode's solution (pH 7.4), containing 5.1% BSA and a mixture of L-amino acids (Sigma Chemical Co). 19 The kidney was excised and prepared as previously described 4,18 -22 so that the vasculature of the juxtamedullary nephrons was directly visualized and the papilla remained intact. The arterial supply of the exposed microvasculature was isolated by ligating the large branches of renal artery with fine suture (nylon black monofilament, 10-0; Surgical Specialties Co).
After the dissection was complete, the Tyrode's perfusate was replaced with the reconstituted blood. The perfusion pressure was monitored with a pressure cannula centered in the tip of the perfusion cannula and maintained at 100 mm Hg throughout all experimental protocols. The perfusion pressure was regulated by adjusting the rate of gas inflow into the blood reservoir. The perfusion chamber was warmed, and the inner cortical surface of the kidney was continuously superfused with a warmed (37°C) Tyrode's solution containing 1% BSA.
The tissue was transilluminated on the fixed stage of a Nikon Eclipse microscope (model E600FN). Video images of the microvessels were transferred via a CCD camera (model C2400-75i; Hamamatsu Photonics) through an image processor (model C5510; Hamamatsu Photonics) and recorded on videotape for later analysis (Videocassette Recorder SVO-260; SONY). The inside diameters of the afferent arterioles were measured at 0.25-second intervals with a width analyzer (model C3161; Hamamatsu Photonics) combined with a computer system (MacLab/8s; AD Instruments Pty Ltd) that yielded diameter measurements reproducible to within 0.5 m. The afferent arteriolar diameters were measured at sites that were within 100 m upstream of the glomerulus. A minimum 10-minute equilibration period was allowed before the initiation of each experimental procedure. The average diameter during the final minute of each 5-minute treatment period was used for the statistical analysis of steady-state responses.
Afferent Arteriolar Diameters During Tempol Treatment
The effects of the superoxide dismutase mimetic Tempol on afferent arteriolar diameters were determined in kidneys harvested from WKY and SHR. The afferent arteriolar diameters were measured before and during exposure to increasing concentrations (0.1, 1, 10, and 100 mol/L) of Tempol (Sigma Chemical Co).
Effects of Tempol on Afferent Arteriolar Responses to nNOS and NOS Inhibition
To study the effects of O 2 Ϫ on the regulation of afferent arteriolar diameters by nNOS and eNOS, afferent arteriolar constrictor responses to the selective nNOS inhibitor S-methyl-L-thiocitrulline (L-SMTC; Sigma Chemical Co) and the NOS inhibitor N -nitro-Larginine (L-NNA; Sigma Chemical Co) were assessed in kidneys harvested from WKY and SHR. The afferent arteriolar diameters were measured before and during exposure to 10 mol/L L-SMTC and an additional exposure to 100 mol/L L-NNA. The same assessment was also performed in the presence of 100 mol/L Tempol with another group of rats.
Statistical Analysis
The changes in afferent arteriolar diameters resulting from treatment with Tempol and the NOS inhibitors were analyzed with 1-way ANOVA for repeated measures combined with the Newman-Keuls post hoc test. Differences in afferent arteriolar responses to NOS inhibitors in the absence and presence of Tempol treatments were determined with 2-way ANOVA for repeated measures combined with the Newman-Keuls post hoc test. A value of PϽ0.05 was considered significant. Data are presented as meanϮSEM.
Results
Systolic arterial pressure was measured with tail-cuff plethysmography immediately before the experiment. In the present study, the systolic arterial pressure of SHR (183Ϯ2 mm Hg, nϭ28) was significantly higher than that of WKY (120Ϯ1 mm Hg, nϭ18). Figure 1 shows the dose-response effects of Tempol on afferent arteriolar diameters in WKY and SHR. In WKY, the control diameter of the afferent arterioles averaged 21.6Ϯ1.6 m (nϭ6). Superfusion with 0.1, 1, 10, and 100 mol/L tempol did not influence the afferent arteriolar diameters. In SHR, however, the control diameter of the afferent arterioles averaged 18.8Ϯ1.2 m (nϭ7) and was significantly smaller than that observed in WKY. The afferent arteriolar diameters increased significantly by 6.6Ϯ3.7%, 20.6Ϯ5.5%, 25.2Ϯ5.4%, and 23.3Ϯ4.9% in response to 0.1, 1, 10, and 100 mol/L Tempol, respectively. To test whether the vasodilation observed during the Tempol treatment enhanced the vasoconstrictor responses to L-SMTC and L-NNA in SHR, the afferent arteriolar responses to L-SMTC and L-NNA were also assessed in a group of kidneys treated with the NO donor S-nitroso-Nacetylpenicillamine (SNAP; Sigma Chemical Co). As shown in Figure 3 , the control diameter of the afferent arterioles in this group averaged 19.3Ϯ1.2 m (nϭ6), and the diameter increased to 22.6Ϯ1.5 m after continuous exposure to 10 mol/L SNAP. The afferent arteriolar diameter increased by an average of 17.2Ϯ2.3% and was similar to the increase that was observed during the treatment with 100 mol/L Tempol (22.5Ϯ4.3%). In the SNAP-treated kidneys, L-SMTC did not influence the afferent arteriolar diameters, whereas L-NNA significantly decreased the afferent arteriolar diameters by 18.6Ϯ2.3%. The responses to L-SMTC and L-NNA were similar to those obtained in untreated kidneys.
Afferent Arteriolar Diameters during Tempol Treatment
Effects of Tempol on Afferent Arteriolar Responses to nNOS and NOS Inhibition
Discussion
A recent study demonstrated that the renal cortex of SHR contains increased protein levels of nitrotyrosine, which is formed by the interaction of tyrosine residues and ONOO Ϫ . 14 Because O 2 Ϫ interacts with NO to yield ONOO Ϫ , the data suggested that the renal cortex of SHR has an increased level of O 2
Ϫ . The present study demonstrated that the removal of O 2 Ϫ by the superoxide dismutase mimetic Tempol elicits a vasodilator response in the afferent arterioles of SHR but not in the afferent arterioles of WKY. This result suggests at least that O 2 Ϫ promotes vasoconstriction in the afferent arterioles of SHR, although further biochemical studies will be required to confirm that increased levels of O 2 Ϫ radicals prevail at the juxtaglomerular apparatus in SHR but not in WKY. Thus, increased renal levels of O 2 Ϫ may contribute significantly to the regulation of afferent arteriolar diameters in SHR.
In the kidney of SHR, nNOS inhibition by L-SMTC did not influence the afferent arteriolar diameters, although the same concentration of L-SMTC significantly constricted the afferent arterioles in WKY. This result indicates that the influence of nNOS on afferent arterioles is reduced in SHR compared with WKY. However, NOS inhibition by L-NNA produced a similar decrease in afferent arteriolar diameters in both SHR and WKY, suggesting that the influence of NOS on afferent arterioles is maintained in SHR. Thus, the influence of nNOS on afferent arterioles must be drastically reduced in SHR. During the Tempol treatment, L-SMTC exerted a vasoconstrictor response in the afferent arterioles of SHR, but the tempol treatment did not influence the responses to L-SMTC or L-NNA in the afferent arterioles of WKY. These results suggest that Tempol treatment restores the reduced influence of nNOS on the afferent arterioles of SHR. In addition, L-SMTC did not influence the afferent arteriolar diameters of SHR in kidneys treated with 10 mol/L SNAP, causing the afferent arterioles to dilate to the same extent as that observed for the treatment with 100 mol/L Tempol. Consequently, the vasodilation observed during the Tempol treatment probably does not enhance the vasoconstrictor response to L-SMTC. Instead, the removal of O 2 Ϫ by Tempol probably restores the impaired regulation of nNOS-dependent afferent arteriolar diameters. The inactivation of NO by O 2 Ϫ may account for the impaired nNOS-dependent control of afferent arteriolar diameters in SHR.
Although the afferent arteriolar responses to L-NNA were also enhanced during the Tempol treatment, the percentage by which the afferent arteriolar response to L-NNA increased with Tempol (16.0%) was similar to the percentage by which the afferent arteriolar response to L-SMTC increased with Tempol (17.1%). These data suggest that O 2 Ϫ mainly scavenges the NO derived from nNOS but does not modulate eNOS-derived NO to a great extent in SHR. Bosse and Bachmann 23 demonstrated that nitrotyrosine immunoreactivity is prominently expressed in the interstitium and the extraglomerular mesangial cells between the macula densa and the afferent arteriole in the 2-kidney, 1-clip Goldblatt hypertensive rat. This finding suggests that O 2 Ϫ is mainly produced in the interstitium and the extraglomerular mesangial cells between the macula densa and the afferent arteriole in hypertensive models. Therefore, O 2 Ϫ may predominantly inhibit the influence of nNOS on afferent arteriolar diameters in SHR by scavenging the NO generated in the macula densa.
Continuous exposure to the NO donor SNAP (10 mol/L) significantly increased the afferent arteriolar diameters in SHR. The increase in afferent arteriolar diameter produced with the SNAP treatment (17Ϯ2%) was similar to that observed in normotensive Sprague-Dawley rats (19Ϯ2%). 24 These results suggest that a large amount of exogenous NO overwhelms the inactivation by O 2 Ϫ and exerts a similar vasodilation effect in normotensive rats and SHR. Therefore, the NO-vasodilation capacity of the afferent arterioles in SHR is similar to that of normotensive rats.
NO derived from nNOS contributes to the counteraction of tubuloglomerular feedback (TGF) responses through buffering of TGF-mediated afferent arteriolar constriction 20 and inhibition of sodium chloride reabsorption by the macula densa cells. 25 During chronic nNOS inhibition, the enhanced TGF response causes the arterial pressure to increase in rats. 26 Because studies have demonstrated an enhanced TGF response 27 and a decreased role of NO in the TGF response 9, 28 in SHR, the reduced influence of nNOS on the TGF response may play a role in the development of hypertension in SHR. Welch et al 14 recently reported that the overproduction of O 2 Ϫ inactivates NO around the juxtaglomerular apparatus, thus contributing to the reduced role of NO in the TGF response. The present study provides direct evidence that the interaction between O 2 Ϫ and nNOS-derived NO plays an important role in the regulation of afferent arteriolar diameters in SHR. Therefore, an increased level of O 2 Ϫ in the kidneys of SHR may contribute to the enhanced TGF response by diminishing the influence of nNOS on the afferent arterioles.
Because the afferent arterioles of juxtamedullary nephrons supply the renal medullary blood flow, the present findings in juxtamedullary nephrons may also indicate an important role in the medullary hemodynamics of SHR. Previous studies have demonstrated that alterations in medullary blood flow in response to changes in renal arterial pressure are blunted in SHR. 29 This blunted response reportedly resembles that observed in rats treated with the NOS inhibitor N G -nitro-Larginine-methyl ester. 30, 31 In addition, the administration of L-arginine, a substrate for NOS, was shown to restore the blunted relationship between medullary blood flow and renal arterial pressure. 31 These findings suggest that an impaired NO system may contribute to the blunted blood flow response to changes in pressure in the renal medulla of SHR. Because nNOS inhibition with L-SMTC enhanced the pressureinduced vasoconstriction in afferent arterioles of the juxtamedullary nephrons, 22 the inactivation of NO by O 2 Ϫ may diminish the ability of the medullary blood flow to increase in response to increases in renal arterial pressure by inhibiting nNOS-dependent regulation of afferent arterioles in the juxtamedullary nephrons of SHR.
In conclusion, Tempol significantly decreased the afferent arteriolar diameters in SHR but did not modulate the afferent arteriolar diameters in WKY, suggesting that O 2 Ϫ significantly contributes to the control of afferent arteriolar diameters in SHR. In addition, the afferent arterioles of SHR constricted in response to the NOS inhibition but did not respond to the selective inhibition of nNOS. Because the removal of O 2 Ϫ restored the impaired response to nNOS inhibition, O 2 Ϫ probably selectively inactivates nNOSgenerated NO. In the kidney of SHR, O 2 Ϫ may contribute to the regulation of afferent arteriolar diameters by scavenging the NO generated by nNOS.
